{"abstract":"The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive, sublicensable patent license to the University of Washington, located in Seattle, State of Washington, U.S.A. in its rights to the inventions and the patent applications listed in the Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2022/04/28/2022-09156.html","cfr_references":[],"citation":"87 FR 25285","comment_url":null,"comments_close_on":"2022-05-13","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases (NIAID) on or before May 13, 2022 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2022-09156","effective_on":null,"end_page":25286,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2022/04/28/2022-09156.xml","html_url":"https://www.federalregister.gov/documents/2022/04/28/2022-09156/prospective-grant-of-exclusive-license-inter-institutional-agreement-institution-lead-engineered","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2022-09156?publication_date=2022-04-28","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2022-04-28/2022-09156/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":98,"last_updated":"2026-07-28 10:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-04-28/pdf/2022-09156.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-09156.pdf?1651063541","publication_date":"2022-04-28","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2022/04/28/2022-09156.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T17:17:23Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":25285,"subtype":null,"title":"Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Engineered Influenza Neuraminidase Antigens","toc_doc":"Inter-Institutional Agreement-Institution Lead: Engineered Influenza Neuraminidase Antigens","toc_subject":"Licenses; Exemptions, Applications, Amendments etc.:\n","topics":[],"type":"Notice","volume":87}